There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT) and Blueprint Medicines (BPMC) with bullish sentiments.
Sarepta Therapeutics (SRPT)
Raymond James analyst Danielle Brill maintained a Buy rating on Sarepta Therapeutics today and set a price target of $200.00. The company’s shares closed last Wednesday at $143.95.
According to TipRanks.com, Brill is a 5-star analyst with an average return of 22.4% and a 61.5% success rate. Brill covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and PTC Therapeutics.
Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $193.57, implying a 34.7% upside from current levels. In a report issued on September 1, Mizuho Securities also maintained a Buy rating on the stock with a $192.00 price target.
See today’s analyst top recommended stocks >>
Blueprint Medicines (BPMC)
Raymond James analyst Dane Leone maintained a Buy rating on Blueprint Medicines today. The company’s shares closed last Wednesday at $75.98.
According to TipRanks.com, Leone is a 5-star analyst with an average return of 13.7% and a 63.9% success rate. Leone covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Ayala Pharmaceuticals, and Voyager Therapeutics.
Blueprint Medicines has an analyst consensus of Strong Buy, with a price target consensus of $98.91, which is a 34.7% upside from current levels. In a report issued on September 8, Goldman Sachs also maintained a Buy rating on the stock with a $103.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
